tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

APLS Stock Latest News

Apellis announces 5-year GALE data showing SYFOVRE delayed progression of GA
The FlyApellis announces 5-year GALE data showing SYFOVRE delayed progression of GA
6d ago
APLS
Promising Potential of Empaveli in Kidney Disease Treatment Drives Buy Rating for Apellis Pharmaceuticals
PremiumRatings
Promising Potential of Empaveli in Kidney Disease Treatment Drives Buy Rating for Apellis Pharmaceuticals
8d ago
APLS
Caterpillar upgraded, Elf Beauty downgraded: Wall Street’s top analyst calls
PremiumThe Fly
Caterpillar upgraded, Elf Beauty downgraded: Wall Street’s top analyst calls
12d ago
FN
CAT
Hold Rating on Apellis Pharmaceuticals: Balancing Stagnant Revenue Growth and Market Challenges
PremiumRatings
Hold Rating on Apellis Pharmaceuticals: Balancing Stagnant Revenue Growth and Market Challenges
13d ago
APLS
Apellis initiated with a Peer Perform at Wolfe Research
PremiumThe Fly
Apellis initiated with a Peer Perform at Wolfe Research
13d ago
APLS
Apellis price target lowered to $36 from $40 at JPMorgan
PremiumThe FlyApellis price target lowered to $36 from $40 at JPMorgan
13d ago
APLS
Apellis price target lowered to $19 from $24 at Mizuho
Premium
The Fly
Apellis price target lowered to $19 from $24 at Mizuho
15d ago
APLS
Apellis Pharmaceuticals’ Earnings Call Highlights FDA Approval and Market Challenges
Premium
Company Announcements
Apellis Pharmaceuticals’ Earnings Call Highlights FDA Approval and Market Challenges
18d ago
APLS
Apellis price target lowered to $45 from $50 at TD Cowen
PremiumThe Fly
Apellis price target lowered to $45 from $50 at TD Cowen
18d ago
APLS
Apellis price target raised to $52 from $50 at Baird
PremiumThe Fly
Apellis price target raised to $52 from $50 at Baird
18d ago
APLS
Apellis price target lowered to $45 from $52 at Citi
PremiumThe Fly
Apellis price target lowered to $45 from $52 at Citi
18d ago
APLS
Apellis price target lowered to $45 from $57 at H.C. Wainwright
PremiumThe Fly
Apellis price target lowered to $45 from $57 at H.C. Wainwright
18d ago
APLS
Apellis Pharmaceuticals Reports Strong Q3 2025 Earnings
PremiumCompany AnnouncementsApellis Pharmaceuticals Reports Strong Q3 2025 Earnings
19d ago
APLS
Apellis Pharmaceuticals: Strong Market Position and Growth Potential Amidst Challenges
Premium
Ratings
Apellis Pharmaceuticals: Strong Market Position and Growth Potential Amidst Challenges
19d ago
APLS
Resilient Revenue and Strategic Positioning Support Buy Rating for Apellis Pharmaceuticals
Premium
Ratings
Resilient Revenue and Strategic Positioning Support Buy Rating for Apellis Pharmaceuticals
19d ago
APLS
Apellis price target lowered to $27 from $29 at BofA
PremiumThe Fly
Apellis price target lowered to $27 from $29 at BofA
19d ago
APLS
Apellis falls -24.8%
PremiumThe Fly
Apellis falls -24.8%
19d ago
APLS
Midday Fly By: Big Tech reports, Novo tops Pfizer bid for Metsera
PremiumThe Fly
Midday Fly By: Big Tech reports, Novo tops Pfizer bid for Metsera
19d ago
BA
CI
Apellis falls -19.3%
PremiumThe Fly
Apellis falls -19.3%
19d ago
APLS
Buy Rating for Apellis Pharmaceuticals Driven by Strong Financial Performance and Promising Product Developments
PremiumRatingsBuy Rating for Apellis Pharmaceuticals Driven by Strong Financial Performance and Promising Product Developments
19d ago
APLS
Positive Outlook for Apellis Pharmaceuticals: Strong Performance and Strategic Positioning Support Buy Rating
Premium
Ratings
Positive Outlook for Apellis Pharmaceuticals: Strong Performance and Strategic Positioning Support Buy Rating
19d ago
APLS
Apellis reports Q3 EPS $1.71, consensus 94c
Premium
The Fly
Apellis reports Q3 EPS $1.71, consensus 94c
19d ago
APLS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >